NEUROVASCULAR clinical
Learn more about our ongoing commitment to research.
Your browser is out of date
With an updated browser, you will have a better Medtronic web site experience. Update my browser now.
Learn more about our ongoing commitment to research.
The New England Journal of Medicine has featured the first-of-its-kind Solitaire™ thrombectomy device 5 times. Solitaire is designed to remove a clot and reduce stroke-related disability in patients suffering from AIS with large-vessel occlusion following IV t-PA.
Proven to provide over 95% occlusion and 0% recurrence at 5 years for patients with follow-up3, Pipeline™ embolization device is the first flow diversion device approved by the FDA for its safety and efficacy. Today, with over 5 years of clinical research, it’s still the most studied flow diverter worldwide.
Do you need support for procedures? Or information on our products and solutions?
Our team is happy to help answer any questions you may have.
CONTACT USPMA- P100018-S011
Scientific Communication Document search (2018) showing clinical summaries. No other studies meet these criteria.
Becske T. et al., Long-Term Clinical and Angiographic Outcomes Following Pipeline Embolization Device Treatment of Complex Internal Carotid Artery Aneurysms: Five-Year Results of the Pipeline for Uncoilable or Failed Aneurysms Trial., (JNS) Neurosurgery Published online Jan 9, 2017.